Trifluoroacetyl Tripeptide-2
Trifluoroacetyl Tripeptide-2 is a cosmetic firming peptide. Supplier research describes inhibition of progerin, a truncated lamin A isoform that accumulates in ageing cells and is associated with altered nuclear morphology, together with effects on myofibroblast contractility intended to improve skin firmness.
For research use only.
Key Facts
- CAS
- 64577-63-5
- Molecular Weight (MW)
- 475.5 g/mol
- Half-life
- —
- FDA status
- Not Approved
- Administration Route
- topical
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Fluorinated tripeptide marketed in topical firming products, sold commercially under the Progeline name. Regulated as a cosmetic ingredient; not FDA-approved as a drug.
Peptide Library's Trifluoroacetyl Tripeptide-2 profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- topical
- Reconstitution Guide
- —
Sequence & molecular data
| Molecular formula | C21H28F3N3O6 |
|---|---|
| Molecular weight | 475.5 g/mol |
| CAS number | 64577-63-5 |
| PubChem CID | 40785040 |
| FDA UNII | E6WT9V3SGO |
| ChEMBL | CHEMBL3138715 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Supplier research describes inhibition of progerin, a truncated lamin A isoform that accumulates in ageing cells and is associated with altered nuclear morphology, together with effects on myofibroblast contractility intended to improve skin firmness. The progerin rationale derives from premature-ageing biology; its relevance to normal skin ageing at cosmetic concentrations has not been independently established.
Studies
- Topical peptides as cosmeceuticals (class-level)
- Skin ageing and topical rejuvenation strategies (class-level)
- Hutchinson-Gilford Progeria Syndrome: Cellular Mechanisms and Therapeutic Perspectives (class-level evidence)
- In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice (class-level evidence)
- Hutchinson-Gilford progeria syndrome (class-level evidence)
Regulatory & research status
Trifluoroacetyl Tripeptide-2 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Research status | Research-only compound; no approval pathway listed |
| Availability | OTC / Supplement |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Cosmetic peptides in this library are formulated into topical products; follow the product label rather than the reconstitution guidance above.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Trifluoroacetyl Tripeptide-2: frequently asked questions
What is Trifluoroacetyl Tripeptide-2?
Fluorinated tripeptide marketed in topical firming products, sold commercially under the Progeline name. Regulated as a cosmetic ingredient; not FDA-approved as a drug.
How does Trifluoroacetyl Tripeptide-2 work?
Supplier research describes inhibition of progerin, a truncated lamin A isoform that accumulates in ageing cells and is associated with altered nuclear morphology, together with effects on myofibroblast contractility intended to improve skin firmness. The progerin rationale derives from premature-ageing biology; its relevance to normal skin ageing at cosmetic concentrations has not been independently established.
Is Trifluoroacetyl Tripeptide-2 FDA approved?
No. Trifluoroacetyl Tripeptide-2 is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Trifluoroacetyl Tripeptide-2?
Compounds most often compared with Trifluoroacetyl Tripeptide-2 include Acetyl Tetrapeptide-3, Biotinoyl Tripeptide-1, Decapeptide-12 and Myristoyl Pentapeptide-17. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Class-level evidence — Topical peptides as cosmeceuticals. Indian J Dermatol Venereol Leprol, 2017External reference
- Class-level evidence — Skin ageing and topical rejuvenation strategies. Br J Dermatol, 2023External reference
- Class-level evidence — Hutchinson-Gilford Progeria Syndrome: Cellular Mechanisms and Therapeutic Perspectives — Arch Med Res, 2023External reference
- Class-level evidence — In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice — Nature, 2021External reference
- Class-level evidence — Hutchinson-Gilford progeria syndrome — Handb Clin Neurol, 2015External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Trifluoroacetyl Tripeptide-2 profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Trifluoroacetyl Tripeptide-2 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →